ArticleInvestigational new drugs2021
A critical appraisal of Japan's new drug approval process: a case study of FLT3-ITD inhibitor quizartinib.
Keisuke Kidoguch et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it